State of Alaska Department of Revenue Sells 1,273 Shares of Dynavax Technologies Corporation $DVAX

State of Alaska Department of Revenue lowered its position in Dynavax Technologies Corporation (NASDAQ:DVAX) by 1.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 66,467 shares of the biopharmaceutical company’s stock after selling 1,273 shares during the period. State of Alaska Department of Revenue owned approximately 0.06% of Dynavax Technologies worth $658,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Exchange Traded Concepts LLC grew its position in shares of Dynavax Technologies by 4.3% in the 2nd quarter. Exchange Traded Concepts LLC now owns 133,601 shares of the biopharmaceutical company’s stock worth $1,325,000 after buying an additional 5,523 shares during the last quarter. Strs Ohio purchased a new position in shares of Dynavax Technologies in the 1st quarter worth approximately $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Dynavax Technologies by 7.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 450,089 shares of the biopharmaceutical company’s stock worth $5,838,000 after buying an additional 29,764 shares during the last quarter. Woodline Partners LP grew its position in shares of Dynavax Technologies by 48.4% in the 1st quarter. Woodline Partners LP now owns 1,178,763 shares of the biopharmaceutical company’s stock worth $15,289,000 after buying an additional 384,288 shares during the last quarter. Finally, Caxton Associates LLP purchased a new position in shares of Dynavax Technologies in the 1st quarter worth approximately $225,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Analyst Ratings Changes

DVAX has been the topic of a number of analyst reports. Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price objective on shares of Dynavax Technologies in a research report on Friday, August 22nd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research report on Saturday, September 27th. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Dynavax Technologies currently has a consensus rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Price Performance

DVAX stock opened at $10.14 on Wednesday. The firm’s fifty day simple moving average is $10.23 and its 200-day simple moving average is $10.60. The company has a market capitalization of $1.19 billion, a P/E ratio of -22.04 and a beta of 1.13. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. Dynavax Technologies Corporation has a 12 month low of $9.20 and a 12 month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. The business had revenue of $95.44 million for the quarter, compared to the consensus estimate of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. As a group, equities research analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, Director Scott Dunseth Myers acquired 3,800 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were acquired at an average cost of $10.82 per share, with a total value of $41,116.00. Following the acquisition, the director directly owned 35,004 shares of the company’s stock, valued at approximately $378,743.28. The trade was a 12.18% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 2.98% of the stock is owned by company insiders.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.